Theranos founder Elizabeth Holmes faces trial next summer
Posted on July 01, 2019 by Medtech[y] Staff
According to TechCrunch, Theranos founder, Elizabeth Holmes, will officially go to trial in San Jose next year, beginning in August 2002, with jury selection beginning on July 28th, 2020.
The story of Theranos and their disgrace founder has been played over the last two years in books, movies, news stories and podcasts. After dropping out of Stanford, Holmes founded Theranos in 2003, claiming that the company had developed a device to conduct several different blood tests from a single drop of blood.
Holmes was quickly turned into a media darling, hanging with celebrities and being named the world's youngest self-made woman billionaire by Forbes.
The narrative of Theranos changed forever after the WSJ reported in 2015 that the company's claims of their technology were lies, stating Holmes and others had covered up results proving that the Theranos technology didn't work.
Federal prosecutors indicted Holmes and the company’s former president and COO (and Holmes' boyfriend), Ramesh “Sunny” Balwani last summer. They were both charged with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. The pair face 20 years in prison and hundreds of thousands of dollars in fines.
Are you a recruiter or company looking to fill a Medical Sales opening, including the medical device or biotech industries? If so, checkout Medtechy Jobs and create a free employer account or a free candidate account. All of our jobs are strategically distributed to our diverse following of experienced and those new to the industry. Multi-pack jobs start at $100.
We are also excited to launch Medtechy Deals, our new store which sources deals on gadgets, everyday carry essentials and online courses for employees in the healthcare industry!
Please follow us on Facebook, Twitter, and LinkedIn for the latest medical technology news, medical device/biotech company intel and career opportunities. You can also sign up for our monthly newsletter.